Company: RCUS
Filing Date: 2025-02-20
Form Type: SCHEDULE 13D/A
Source: 0001123292-25-000105
Chunk: 0

Company: Arcus Biosciences, Inc.
Filing Date: 2025-02-20
Form: SCHEDULE 13D/A
Chunk 0
---
) |
| 13                                                                 |                                                                                 35 % |
| 14                                                                 |                                                                                   CO |

Comment for Type of Reporting Person: The number of shares reported in rows 7, 9, and 11 consists of (i) 2,200,000 shares of the common stock, par value $0.0001 per share (the "Common Stock"), of Arcus Biosciences, Inc. (the "Issuer") purchased in the 2020 Public Offering (as defined below), (ii) the initial purchase of 5,963,029 shares of Common Stock pursuant to a Common Stock Purchase Agreement, dated May 27, 2020, between Gilead Sciences, Inc. and the Issuer (the "Purchase Agreement"), (iii) the subsequent purchase of 5,650,000 shares of Common Stock pursuant to an Amended and Restated Common Stock Purchase Agreement, dated January 31, 2021, between Gilead Sciences, Inc. and the Issuer (the "Amended and Restated Purchase Agreement"), (iv) the subsequent purchase of 1,010,000 shares of Common Stock pursuant to a Second Amended and Restated Common Stock Purchase Agreement (the "Second Amended and Restated Purchase Agreement"), (v) the subsequent purchase of 15,238,095 shares of Common Stock of the Issuer pursuant to a Third Amended and Restated Common Stock Purchase Agreement (the "Third Amended and Restated Purchase Agreement"), (vi) the subsequent purchase of 1,363,636 shares of Common Stock pursuant to the Public Offering (as defined below), and (vii) the number of shares of Common Stock that would result in Gilead Sciences, Inc. holding 35% of the Issuer's then-outstanding Common Stock pursuant to a five-year option to purchase additional shares of Common Stock contained in the Third Amended and Restated Purchase Agreement (the "Option Shares"). Based upon 105,137,824 shares of Common Stock of the Issuer issued and outstanding upon the closing of the Public Offering, as disclosed in the prospectus supplement (the "Prospectus Supplement") filed with the Securities and Exchange Commission (the "SEC") on February 18, 2025 pursuant to Rule 424(b)(5) under the Securities Act of 1933, as amended, the number of Option Shares is currently equal to 8,266,889. The percent reported in row 13 is calculated based upon 113,